Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edward L. Giovannucci, D.Sc., M.D.

Co-Author

This page shows the publications co-authored by Edward Giovannucci and Michelangelo Fiorentino.
Connection Strength

1.495
  1. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 08; 27(8):1043-7.
    View in: PubMed
    Score: 0.167
  2. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
    Score: 0.137
  3. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.137
  4. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.117
  5. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.109
  6. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
    View in: PubMed
    Score: 0.098
  7. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):751-756.
    View in: PubMed
    Score: 0.057
  8. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018 12 31; 39(12):1431-1437.
    View in: PubMed
    Score: 0.050
  9. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur Urol. 2019 07; 76(1):33-40.
    View in: PubMed
    Score: 0.049
  10. Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):193-200.
    View in: PubMed
    Score: 0.046
  11. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. Prostate. 2017 May; 77(6):647-653.
    View in: PubMed
    Score: 0.043
  12. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer. 2016 Apr 12; 114(8):939-44.
    View in: PubMed
    Score: 0.041
  13. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016 Mar; 103(3):851-60.
    View in: PubMed
    Score: 0.041
  14. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.040
  15. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb 01; 22(3):765-772.
    View in: PubMed
    Score: 0.040
  16. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun; 36(6):639-47.
    View in: PubMed
    Score: 0.038
  17. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
    View in: PubMed
    Score: 0.038
  18. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.036
  19. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.035
  20. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
    View in: PubMed
    Score: 0.035
  21. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.032
  22. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.030
  23. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
    View in: PubMed
    Score: 0.028
  24. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.028
  25. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.